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Somatic hypermutation (SHM) of antibody variable region genes is
initiated in germinal center B cells during an immune response by
activation-induced cytidine deaminase (AID), which converts cyto-
sines to uracils. During accurate repair in nonmutating cells, uracil
is excised by uracil DNA glycosylase (UNG), leaving abasic sites
that are incised by AP endonuclease (APE) to create single-strand
breaks, and the correct nucleotide is reinserted by DNA polymerase
β. During SHM, for unknown reasons, repair is error prone. There
are two APE homologs in mammals and, surprisingly, APE1, in con-
trast to its high expression in both resting and in vitro-activated
splenic B cells, is expressed at very low levels in mouse germinal
center B cells where SHM occurs, and APE1 haploinsufficiency has
very little effect on SHM. In contrast, the less efficient homolog,
APE2, is highly expressed and contributes not only to the frequency
of mutations, but also to the generation of mutations at A:T base
pair (bp), insertions, and deletions. In the absence of both UNG and
APE2, mutations at A:T bp are dramatically reduced. Single-strand
breaks generated by APE2 could provide entry points for exonucle-
ase recruited by the mismatch repair proteins Msh2–Msh6, and the
known association of APE2 with proliferating cell nuclear antigen
could recruit translesion polymerases to create mutations at AID-
induced lesions and also at A:T bp. Our data provide new insight
into error-prone repair of AID-induced lesions, which we propose is
facilitated by down-regulation of APE1 and up-regulation of APE2
expression in germinal center B cells.
During humoral immune responses, the recombined antibodyvariable [V(D)J] region genes undergo somatic hypermutation
(SHM), which, after selection, greatly increases the affinity of
antibodies for the activating antigen. This process occurs in
germinal centers (GCs) in the spleen, lymph nodes, and Peyer’s
patches (PPs) and entirely depends on activation-induced cyti-
dine deaminase (AID) (1, 2). AID initiates SHM by deamination
of cytidine nucleotides in the variable region of antibody genes,
converting the cytosine (dC) to uracil (dU) (1, 3, 4). Some AID-
induced dUs are excised by the ubiquitous enzyme uracil DNA
glycosylase (UNG), resulting in abasic (AP) sites that can be
recognized by apurinic/apyrimidinic endonuclease (APE) (4, 5).
APE cleaves the DNA backbone at AP sites to form a single-
strand break (SSB) with a 3′ OH that can be extended by DNA
polymerase (Pol) to replace the excised nucleotide (6). In most
cells, DNA Pol β performs this extension with high fidelity,
reinserting dC across from the template dG. In contrast, GC B
cells undergoing SHM are rapidly proliferating, and some of the
dUs are replicated over before they can be excised and are read
as dT by replicative polymerases, resulting in dC to dT transition
mutations. Unrepaired AP sites encountering replication lead to
the nontemplated addition of any base opposite the site, causing
transition and transversion mutations. However, it is not clear
why dUs and AP sites escape accurate repair by the highly effi-
cient enzymes UNG and APE1 and lead instead to mutations.
Instead of removal by UNG, some U:G mismatches created by
AID activity are recognized by the mismatch repair proteins
Msh2–Msh6, which recruit exonuclease 1 to initiate excision of
one strand surrounding the mismatch (7–9). The excised region
(estimated at ∼200 nt; ref. 10) is subsequently filled in by DNA
Pols, including error-prone translesion Pols, which spreads muta-
tions beyond the initiating AID-induced lesion. The combined, but
noncompeting interaction of the UNG and MMR pathways in
generating mutations at A:T base pairs (bp) has been described
(10–12). This mismatch repair-dependent process has been
termed phase II of SHM (3). Pol η and Msh2–Msh6 have been
shown to be essential for nearly all mutations at A:T bp (13–15).
During repair of the excision patch, additional C:G bp can be
mutated by translesion Pols, but mutations at C:G bp due to AID
activity can also be repaired back to the original sequence during
this step (16).
Mammals express two known homologs of AP endonuclease
(APE), APE1 and APE2. APE1 is the major APE; it is ubiqui-
tously expressed and essential for early embryonic development
in mice and for viability of human cell lines (17–19). APE1 has
strong endonuclease activity and weaker 3′-5′ exonuclease (proof-
reading) and 3′-phosphodiesterase (end-cleaning) activities (20, 21).
Recombinant purified human APE2 has much weaker AP endo-
nuclease activity than APE1, but its 3′-5′ exonuclease activity is
strong compared with APE1, although it is not processive (20).
However, APE2 has been shown to interact with proliferating
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cell nuclear antigen (PCNA) (22), which can recruit error-prone
translesion polymerases (23, 24), and PCNA also increases the
processivity of APE2 exonuclease in vitro (25). Both APE1 and
APE2 are expressed in splenic B cells activated in culture (26).
APE2 is nonessential, but APE2-deficient mice show a slight
growth defect, a twofold reduction of peripheral B and T cells
(27), and impaired proliferation of B-cell progenitors in the bone
marrow (28).
In this study we examine SHM in GC B cells isolated from the
PPs of unimmunized apex1+/−, apex2Y/−, and apex1+/−apex2Y/−
mice relative to WT mice. [Because the APE2 gene is located on
the X chromosome, we used APE2-deficient male mice (apex2Y/−)
in all experiments.] We demonstrate that not only is APE2 im-
portant for SHM frequency, as reported (29), but APE2 also
contributes to the generation of A:T mutations. The proportion of
mutations at A:T bp is reduced in apex2Y/−mice to the same extent
as it is in ung−/− mice, consistent with APE2 acting as an endo-
nuclease that incises AP sites generated by UNG. Surprisingly, in
the absence of both UNG and APE2, mutations at A:T bp are
greatly reduced. In addition, we find that expression of APE1 is
dramatically reduced in GC B cells, and APE1 haploinsufficiency
has very little effect on SHM.We propose a model in which APE2
promotes SHM through inefficient and error-prone repair, whereas
APE1, which is known to interact with XRCC1 and Pol β to pro-
mote error-free SSB repair (30, 31), is suppressed in GC B cells.
Results
APE1 Is Down-Regulated and APE2 Is Up-Regulated in GC Cells. Pre-
viously we showed that APE1 is constitutively expressed and
APE2 is inducibly expressed in mouse splenic B cells induced to
undergo CSR in culture (26). Because these cultured B cells do
not undergo SHM, which occurs only in vivo in GCs, we com-
pared the expression of APE1 and APE2 in total cell extracts of
GC and non-GC cells from PPs. Surprisingly, APE1 is expressed
at dramatically lower levels in GC B cells than in non-GC B cells,
whereas APE2 expression is greatly induced in GC cells (Fig. 1 A
and B). APE1 expression is also lower in GC B cells than in
spleen B cells activated in culture with LPS and IL-4 (P < 0.008).
The expression of APE1 in human tonsil GCs is also very low, as
shown by immunohistochemistry (32), The Human Protein Atlas
(www.proteinatlas.org). In contrast, we showed that DNA Pol β
is expressed equally in mouse GC and non-GC B cells, and in
spleen B cells activated in culture (33). The low level of APE1 is
reflected in its very low mRNA level relative to that of APE2
mRNA, using quantitative PCR primers that amplify equally
efficiently (Fig. 1C). Recent reports have also shown low levels
of APE1 transcripts in the GC (34, 35), especially in the rapidly
proliferating centroblasts of the dark zone, relative to centrocytes
in the light zone where selection occurs. Cultured spleen B cells
express roughly equivalent amounts of APE1 and APE2 mRNA
(Fig. 1D), similar to results for protein levels. APE2 is clearly
important for the proliferation and/or survival of GC B cells, be-
cause APE2 deficiency causes a twofold reduction in the percent
of B cells that are GL7+GC cells (Fig. 1E). APE1 haploinsufficiency
does not reduce the percent of GC cells, in keeping with the already
very low levels of APE1 expressed.
Analysis of SHM in APE-Deficient Mice. To analyze SHM in apex1+/−,
apex2Y/−, and apex1+/−apex2Y/− mice in comparison with wild-type
(WT) mice, we examined PP GC cells because they are un-
dergoing persistent activation by numerous antigens, thus allow-
ing examination of a large variety of B-cell clones. Similar to
studies by other investigators, we analyzed SHM in a 493-bp
segment located immediately 3′ to JH4 to avoid effects on the
DNA sequences due to selection for antigen specificity (36). GC B
cells were sorted from 7-wk to 9-mo-old unimmunized mice, and
age did not appear to affect the results. APE1-heterozygous mice
were analyzed because apex1−/− mice die during early embryo-
genesis, and APE1 heterozygotes are haploinsufficient and have
DNA repair and CSR deficiencies (26, 37, 38).
Frequency of SHM Is Decreased in apex2Y/− Mice and Not Affected by
APE1 Haploinsufficiency. Table 1 presents the mutation frequency
and base specificity data for the WT and APE-deficient mice.
We analyzed an average of 30,000 nt per mouse, and the average
of the individual mice is shown ± SEM. The data on individual
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Fig. 1. APE1 expression is reduced and APE2 is increased in germinal center (GC) B cells. (A) Western blotting of 20 μg of whole-cell extract from FACS-
purified PP GC and non-GC B cells, or spleen B cells activated in vitro for 48 h with LPS, IL-4, and BLyS. Anti-Grb2 or anti-GAPDH antibody was used as a loading
control; two representative blots from three independent sorting experiments are shown. (B) Protein expression levels relative to non-GC B cells determined
by densitometry analysis of Western blots (mean ± SEM, n = 3). Results were normalized to Grb2 levels. APE1 levels in non-GC B cells were arbitrarily set at 1.0;
APE2 levels in non-GC B were set at 0.2, which represented the average ratio of APE2 to APE1 in non-GC B cells, relative to the loading control. **P < 0.004;
*P < 0.03; paired t test analysis. APE1 in GC B cells is also reduced relative to spleen B cells activated in vitro (P < 0.008). (C and D) mRNA expression levels,
relative to 18S rRNA, in GC B cells (C) (mean ± SEM, n = 4) and spleen B cells activated in vitro (D) (n = 2 for WT 24h and 48h, mean ± range, and n = 1 for AID
48h). (E) PP GC cells as a percent of B220+ cells (mean ± SEM, n = 5 except for apex1+/−apex2Y/−, n = 4); *P < 0.05.
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mice, and the number of nts sequenced and mutations analyzed
are reported in Table S1. Relative toWTmice, SHM in the JH4–3′
intron is essentially unaffected by apex1 haploinsufficiency. Al-
though we cannot fully assess the impact of APE1 deficiency on
SHM because we can only study apex1 heterozygotes, it is clear
from the mutation frequencies and base specificity that APE1 has
very little role in this process, consistent with its very low expres-
sion levels in GC B cells. In contrast, the mutation frequency is
reduced by 50% in apex2Y/− mice, as shown (29), and also in
apex1+/−apex2Y/− mice. The contribution of APE2 toward muta-
tion frequency may be either direct, as discussed below, or in-
direct, because APE2 is important for B-cell proliferation and
survival (28), and the percentage of GC B cells is reduced in its
absence. However, because the nucleotide specificity of mutations
is also altered in the absence of APE2, we conclude that APE2 has
a direct role in SHM.
Decreased Mutations at A:T Base Pairs in apex2Y/− Mice. Although
SHM is initiated by the deamination of dC by AID, 59% of the
mutations (after correction for the base composition of the se-
quence) in WT mice are at A:T bp. A:T mutations are generated
by the activities of Msh2-Msh6 and Pol η, which require SSBs as
entry points to initiate excision and translesion synthesis (5, 39).
The percent of mutations occurring at A:T bp is decreased to
48% (P < 0.001) in mice that lack APE2 and to 46% in both
apex1+/−apex2Y/− mice and ung−/− mice (Table 1). Apex1+/− mice
have only a very small decrease in A:T mutations, which is not
statistically different from WT. The percent of mutations at
AID-target hotspots (WRC/GYW) is also slightly, but signifi-
cantly, increased from 18% in WT to 24% of mutations in the
absence of APE2. Based on these data, we propose that APE2
functions as an endonuclease creating SSBs at AP sites gener-
ated by AID and UNG activities that allow mismatch repair and
Pol η to generate mutations at surrounding A:T bp. However,
because nearly half of the mutations are still at A:T bp, it is clear
that there is another source of SSBs for creating mutations at
A:T bp.
APE2 Function in the Absence of UNG. Having proposed that APE2
and UNG act in the same pathway, we decided to test this by
creating ung−/−apex2Y/− mice, which we expected would have the
same phenotype with respect to A:T mutations as UNG de-
ficiency. However, as shown in Table 1, ung−/−apex2Y/− mice
have a further twofold reduction in the percent of mutations at
A:T bp (24%; P < 0.001) compared with ung−/−mice and apex2Y/−
mice, and also the proportion of mutations at AID hotspots is 2.6-
fold greater in ung−/−apex2Y/−mice than inWTmice. These results
are surprising because they indicate that APE2 can affect SHM in
the absence of UNG, and suggest that another uracil DNA gly-
cosylase might substitute for UNG during SHM, creating AP sites
that can be incised by APE2. APE1 heterozygosity on an UNG-
deficient background does not alter SHM relative to UNG de-
ficiency alone. Similarly, APE-1 heterozygosity in ung−/−apex2Y/−
mice does not alter SHM significantly relative to ung−/−apex2Y/−
mice (Table 1). These data indicate that APE2 is the predominant
APE for introducing SSBs at AP sites created by the AID-UNG
pathway during SHM, and that backup activity, which may include
SMUG1 (Discussion) and low levels of APE1, is very inefficient at
spreading mutations beyond the initial lesion introduced by AID.
Insertions and Deletions Are Reduced. SSBs made by APE during
SHM could lead to insertion and deletion mutations (indels).
Although this type of mutation is rare within the JH4 3′ inton
during SHM (1.8 × 10−4 per bp in WT mice), we observed a 60%
reduction in the frequency of indels in the absence of APE2
(Table 1), and also in the absence of UNG. The frequency of
indels was reduced by 85% in the ung−/−apex1+/−apex2Y/− mice,
suggesting that some SSBs made by the UNG-APE pathway could
lead to double-strand breaks (DSBs) during SHM. However,
indels can also be introduced by other mechanisms besides DSBs.
Table 1. SHM analysis of the 3′JH4 flank in GC B cells deficient in APE and UNG
Genotype
No. of
mice
Mutation frequency
(x 10−3)*
Percent of mutations
at A:T bp†
Percent of C:G
mutations that
are transitions‡
Percent of
mutations at WRC/GYW
hotspots§
Frequency of
indels (x 10−4){
Wild type 7 22.4 ± 3.5 58.9 ± 1.3 58.5 ± 2.9 17.7 ± 0.7 1.81 ± 0.24
apex1+/− 5 19.2 ± 2.6 55.1 ± 2.4 60.2 ± 1.8 20.3 ± 1.9 2.22 ± 1.02
0.516 0.154 0.675 0.161 0.660
apex2Y/− 5 11.1 ± 2.5 48.3 ± 1.8 63.3 ± 2.6 23.8 ± 1.1 0.77 ± 0.38
0.037 <0.001 0.267 <0.001 0.033
apex1+/−apex2Y/− 5 11.5 ± 1.1 46.2 ± 3.9 66.5 ± 4.2 22.2 ± 0.3 0.99 ± 0.36
0.031 0.005 0.135 <0.001 0.072
ung−/− 3 20.0 ± 1.9 45.6 ± 1.4 90.7 ± 1.5 28.8 ± 1.2 0.71 ± 0.24
0.695 <0.001 <0.001 <0.001 0.024
ung−/−apex1+/− 3 15.5 ± 2.7 41.5 ± 4.0 92.6 ± 1.2 29.3 ± 2.4 0.76 ± 0.23
v. WT 0.275 <0.001 <0.001 <0.001 0.029
v. ung 0.240 0.387 0.521 0.854 0.885
ung−/−apex2Y/− 3 6.5 ± 0.6 24.4 ± 2.1 95.7 ± 1.5 45.6 ± 0.4 0.88 ± 0.64
v. WT 0.022 <0.001 <0.001 <0.001 0.120
v. ung 0.024 0.001 0.170 <0.001 0.808
ung−/−apex1+/−apex2Y/− 4 7.8 ± 1.9 25.0 ± 4.7 97.6 ± 1.1 38.5 ± 2.4 0.27 ± 0.16
v. WT 0.017 <0.001 <0.001 <0.001 0.001
v. ung 0.007 0.015 0.040 0.023 0.170
v. ung/apex2 0.595 0.567 0.349 0.056 0.330
Numbers in italics are P values.
*Mean frequency of mutations/103 bp of individual mice ± SEM; P values, shown below each mean, are from t test of means relative to WT. For data on
individual mice, see Table S1.
†Corrected for sequence composition.
‡The calculations for base specificity exclude identical mutations found in sequences from the same mouse that have the same CDR3.
§AID hotspots defined as WRC/GYW where Y = pyrimidine, W = A or T, R = purine. Mutations counted if they occur at the underlined C or G.
{Insertions and deletions per 104 nt; mean of individual mice ± SEM.
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Transition Mutations at C:G bp Are Slightly Increased in the Absence
of APE2. In WT B cells, 59% of the mutations at C:G bp are
transition mutations, suggesting that many of the dUs introduced
by AID are replicated over before excision by UNG. Although
there is a trend toward increased transition mutations at C:G bp
in the APE-deficient mice (Table 1 and Fig. 2), the difference is
not significant, as might be expected because UNG is present. As
reported by others (4), UNG-deficient mice have greatly in-
creased transitions (91%), and we find that in the absence of
both UNG and APE2, nearly all mutations at C:G are transitions
(96% and 98% in ung−/−apex2Y/− and ung−/−apex1+/−apex2Y/−,
respectively). An alternative uracil DNA glycosylase, acting in
the absence of UNG, could explain the few transversions still
observed in the ung−/− and ung−/−apex1+/−apex2Y/− mice.
To attempt to determine whether APE deficiency affects the
activity of Pol η during SHM, we analyzed the ratio of A:T
mutations, because Pol η shows strand bias with a twofold pref-
erence for mutating A relative to T (40). We observed no con-
sistent changes in the A:T ratio of the mutations (Fig. 2 and Table
S1). These data suggest that another translesion Pol does not
substitute for Pol η in the absence of APE.
Discussion
We report here the surprising finding that expression of APE1,
the highly efficient, essential, and otherwise ubiquitous AP en-
donuclease, is dramatically down-regulated in GC B cells. APE1
is effectively replaced in the GC by APE2, a very inefficient APE
homolog whose expression is greatly induced. We found that
APE2 not only increases the frequency of mutations, but also
specifically increases mutations at A:T bp. We propose that the
decrease in APE1 combined with up-regulation of APE2 in
rapidly dividing GC cells explains a long-standing mystery as to
why repair of AID-induced lesions is error prone.
The reduction in APE1 expression alone could be sufficient to
explain a large portion of phase I mutations, which are generated
when AID-induced lesions at C:G bp are encountered by DNA
polymerase. It has not been clear why dUs and the resulting AP
sites generated by UNG encounter polymerase and give rise to
transitions and transversions in GC B cells, in contrast to their
accurate repair in all other cell types. Reduced APE1 levels
could explain both aspects of this error-prone repair. First, APE1
has been shown to increase the turnover rate of UNG by dis-
placing it from double-stranded AP sites, thus increasing UNG
activity (41). As such, decreased APE1 levels would lead to less
UNG activity, leaving more dUs to encounter polymerase. APE2
might also have this activity, but might be much less efficient
because it is an inefficient endonuclease. Second, it is unlikely
that AP sites would go unrepaired and encounter DNA poly-
merase given normal levels of APE1 expression. The enzymatic
activity of APE1 for AP-site repair has been reported to be from
70- to 450,000-fold more efficient than that of APE2 (20, 21, 42).
In addition, APE1 interacts directly with XRCC1 (30, 43),
a scaffolding protein that recruits Pol β and ligase to promote
SSB repair. This interaction was mapped to the N terminus of
APE1, a unique domain not found in APE2. XRCC1 is an es-
sential gene, but xrcc1+/− mice have slightly increased SHM
frequency (44), demonstrating that this APE1-mediated repair
pathway could suppress SHM. Indeed, the fact that only a small
effect on SHM is seen in xrcc1+/− mice could be due to the very
low levels of APE1 expression in GC cells. Pol β deficiency does
not affect the base specificity of mutations during SHM (33, 45),
consistent with our hypothesis that the APE1-Pol β pathway has
little or no direct effect on SHM. The lack of effect of Pol β likely
results from the very low APE1 expression in GC B cells, as
opposed to our previous interpretation that the BER pathway
does not contribute to SSBs needed for A:T mutations (33). By
contrast, it has recently been shown that mice expressing a mu-
tant Pol β with very slow polymerization kinetics have increased
SHM of the JH4 flank in GC B cells, with the largest effect on
transversions at C:G bp (46). Because Pol β interacts with APE1
and XRCC1 during repair of AP sites (31, 47), this mutant Pol β
might reduce the turnover of APE1, further decreasing the ef-
fective APE1 levels and allowing increased access of APE2 to
AP sites.
In this study, we found that the alternative use of APE2
contributes to SHM in GC B cells. APE2-deficient GC cells are
reduced in number and may proliferate fewer times because of
increased levels of DNA damage, which could contribute in-
directly to the reduced frequency of mutations we and others
(29) observed. However, the fact that the base specificity of the
mutations is also changed indicates that APE2 plays a direct role
in SHM in addition to supporting GC cell proliferation. A:T
mutations, which require SSBs as entry points for recruitment of
exonuclease by Msh2–Msh6 and for Pol η to perform translesion
synthesis, are reduced in apex2Y/− B cells to the exact same extent
as they are in ung−/− cells. This reduction is consistent with APE2
endonuclease incision activity at AP sites generated by UNG.
Although the incision activity of APE2 is weak in biochemical
studies, APE2 is highly expressed in GC B cells and could be
specifically recruited to increase its efficacy. Our previous data
on the role of APE2 in CSR also supports the conclusion that
APE2 acts as an endonuclease at AP sites made by UNG (26).
We showed previously that DSBs occurring at AID hotspots are
near background levels in apex1+/−apex2Y/− B cells, even with one
allele of apex1 intact. Furthermore, A:T mutations induced in
the unrearranged (germ-line) 5′ Sμ segment in cells undergoing
Ig class switching are also reduced in apex1+/−apex2Y/− B cells
relative to WT cells (26).
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Fig. 2. Spectra of mutations in the J558VHFR3-JH4 3′ intron segments in pooled sequences from PP GC B cells from the indicated genotypes. The data are
presented as percent of mutations, corrected for the base composition of the 493-bp segment. Base composition of the 493-bp segment is as follows: A,
26.4%; C, 14.4%; G, 27.2%; T, 31.8%.
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In addition to the inefficient endonuclease activity of APE2,
we hypothesize that an interaction between APE2 and PCNA
also promotes error-prone repair in GCs. Unlike APE1, APE2
has a functional PCNA-interacting domain (48). PCNA mono-
ubiquitinated at lysine 164 is known to recruit the translesional pol-
ymerases Pol η and Rev1 (23), and SHM analyses in mice expressing
a knock-in PCNAK164R mutation show a reduction in A:T mutations
(49, 50). The 3′ to 5′ exonuclease processivity of APE2 is also
stimulated by PCNA (25) and could contribute to mutations by
excising a few nucleotides at a SSB, exposing a short single-
strand patch 5′ to the AP site that could be filled in by Pol η, also
resulting in mutations at A:T bp. This activity could explain the
fact that during SHM, there are some A:T mutations in the
absence of Msh2–Msh6, although Msh2–Msh6 is required for
the vast majority of mutations at A:T bp (7). However, because
the exonuclease activities of APE1 and APE2 are associated with
proofreading functions, it is possible that their activity also cor-
rectly repairs some AID-induced lesions (20, 51).
Because UNG excises the dU base, thus creating the substrate
for APE2, we predicted that mice deficient in both UNG and
APE2 would have the same SHM phenotype as that of UNG-
deficient mice. However, they do not. We find that ung−/−ape2Y/−
mice have a further twofold reduction in the percent of mutations at
A:T bp, with almost half (46%) of the mutations occurring at AID
hotspots. This represents a dramatic decrease in phase II mutations,
demonstrating that the spreading of mutations beyond the initial
lesion made by AID is very inefficient in the absence of both UNG
and APE2. That APE2 and UNG deficiencies affect SHM addi-
tively suggests that UNG and APE2 can each act in alternative
pathways. UNG works very efficiently with APE1 (52), and the low
level of APE1 might partially substitute for APE2 in its absence.
Another uracil DNA glycosylase, such as SMUG1, could substitute
for UNG (53), although SMUG1 is much less efficient than UNG.
It binds AP sites very tightly and depends more on APE for its
turnover (41, 52). Therefore, in ung−/−ape2Y/− GC B cells, which
have SMUG1 and only very low levels of APE1, this pathway would
be very inefficient at generating SSBs that can lead to mutations at
A:T bp. Alternatively, or in addition, our data are consistent with
the possibility that APE2 might incise the DNA backbone at dU
bases, in addition to AP sites, consistent with a recent report (54).
Although APEs are thought to act specifically at AP sites, this study
showed that APE1 can incise DNA at dU in duplex DNA, albeit
inefficiently. APE2 has not been tested for this activity, which would
not be expected to contribute to the process of SHM under normal
conditions, but could impact mutations in the absence of UNG.
It will be interesting to see how our finding of very low APE1
expression in GC B cells impacts current models of CSR. Al-
though the process of CSR is associated with the GC reaction,
class switching also occurs in vivo before GC formation. CSR
requires DSB intermediates and, therefore, might require the
more robust enzymatic activity of APE1. The mechanism and
timing of APE1 down-regulation is unknown, but our results
indicate that it occurs at the RNA level. APE1 might be highly
expressed in cells undergoing CSR in extrafollicular sites and in
B-cell follicles before differentiation of GCs, just as it is in ac-
tivated B cells in culture. Also, the recently reported association
of APE1 with AID (55), dependent on phosphorylation of
AIDSer38, could result in specific recruitment of APE1 in GC B
cells to switch regions to make DSBs required for CSR, thus
overcoming its low level of expression. Although we find that
APE2 contributes to CSR in cultured splenic B cells (26), APE2
does not contribute to CSR in CH12F3 cells (56) possibly due to
specific requirements or genetic alterations of this cell line.
However, because almost all studies to date on the mechanism of
CSR and switch region DSBs have been performed in cultured
cells, more studies on CSR in B cells in vivo are needed. It is
possible that the high levels of APE1 expressed in B cells in-
duced in vitro to undergo CSR could promote accurate repair of
AID-induced lesions in the V region and explain the fact that
SHM has not been observed in cultured B cells.
Materials and Methods
Mice. All mouse strains were backcrossed to C57BL/6 for more than eight
generations and before interbreeding to create double- and triple-deficient
mice. Apex1+/− mice were obtained from E. Friedberg (38) (University of
Texas Southwestern Medical Center, Dallas, TX). APE2-deficient mice were
described (27), and UNG-deficient mice were obtained from T. Lindahl and
D. Barnes (London Research Institute, London, England). Because apex2 is on
the X chromosome, we used male apex2Y/− mice in all experiments. The WT
mice were littermates of either the apex2Y/− or apex1+/−apex2Y/− mice. Mice
were housed in the Institutional Animal Care and Use Committee-approved
specific pathogen-free facility at the University of Massachusetts Medical
School. The mice were bred and used according to the guidelines from the
University of Massachusetts Animal Care and Use Committee.
Analysis and Purification of GC B Cells. PP cells from WT, apex1+/−, apex2Y/−,
and DBL mice were mechanically dispersed and stained with anti–B220-APC,
anti–CD95-PE, anti–GL7-FITC, and 7AAD. Viable (7AAD−), GC (B220+CD95+
GL7+), and non-GC (B220+CD95−GL7−) B cells were isolated on a FACSAriaII
(>92% purity), and frozen for subsequent DNA extraction, or lysed in RIPA
buffer for Western blotting or in TRIzol (Life Technologies) for RNA ex-
traction. WT control spleen cells were T-depleted with antibody and com-
plement and cultured as described (19), with LPS, IL-4, and BLyS.
Western Blotting. Pelleted cells from FACS-purified or cultured B cells were
lysed in RIPA buffer, and 15–20 μg of whole-cell extracts were analyzed on
8% (wt/vol) polyacrylamide gels as described (19) with goat anti-APE1 (R&D
Systems), rabbit anti-APE2 (AnaSpec), and rabbit anti-Grb2 (growth factor
receptor bound protein 2) and anti-GAPDH (glyceraldehyde 3-phosphate de-
hydrogenase) (Santa Cruz) primary antibodies, with goat anti-rabbit and donkey
anti-goat secondary antibodies couple to horseradish peroxidase (Santa Cruz).
Densitometry was performed on a G:BOX Chemi XL (Syngene).
Quantitative RT-PCR. RNA was prepared from cells in TRIzol, and cDNA was
made by using oligo dT and SuperScript II reverse transcriptase (Invitrogen).
Quantitative PCR was performed on a ViiA7 (Applied Bioscience) at 60 °C with
primers for apex1 [Forward (F): 5′- CTCAAGATATGCTCCTGGAA and reverse
(R): 5′- GGTATTCCAGTCTTACCAGA, apex2 (F: 5′- CTTACACAGCACAAGATC-
CG and R: AAAGCATTCCAGACTACTTGC], and 18S RNA (F: 5′- TGGTGGAG-
GGATTTGTCTGG and R: 5′- TCAATCTCGGGTGGCTGAAC. Primers did not
amplify genomic DNA.
Amplification, Cloning, and Sequence Analysis of J558VHFR3-JH4 3′ Intron
Segments. To assay SHM, the VHJ558L framework 3 - JH4 3′ flanking region
was amplified by a nested PCR by using Pfu Ultra II (Stratagene); primers
were modified slightly from ref. 36. Primers for the first amplification were
as follows: F: 5′AGCCTGACATCTGAGGAC and R: 5′ GTGTTCCTTTGAAAGCT-
GGAC. Nested primers for the second amplification were as follows: F: 5′
CCGGAATTCCTGACATCTGAGGACTCTGC and R: 5′ GATGCCTTTCTCCCTTGA-
CTC. The reaction conditions for the first primer set were 95 °C for 30 s, 57°
for 30 s, and 72° for 1 min for 30 cycles; and for the second primer set, they
were 95° for 30 s, 57° for 30 s, and 72° for 1 min for 35 cycles. The PCR
products were electrophoresed on 1% agarose gels; the 600-bp band was
purified by using QIAquick Gel Extraction Kit (Qiagen), dA tails were added
with Taq polymerase, cloned by using TOPO TA cloning kit (Invitrogen), and
sequenced by Macrogen. Unmutated sequences were excluded from the
mutation frequency calculations shown in Table 1 and Table S1, because
individual mice within each genotype, including WT mice, varied in the
proportion of entirely unmutated sequences they have. As such, we cannot
distinguish between sequences that are unmutated because of APE de-
ficiency, and those that are due to contamination by nongerminal center
cells, which could vary between experiments. Because SHM occurs over several
cell generations, sequences with identical CDR3′s will have both shared and
unique mutations. For frequency analyses, we counted all mutations in non-
identical sequences, but for base specificity analyses, we did not include
identical mutations if they were in sequences with identical CDR3’s.
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